AV Access

For patients who require hemodialysis access, 38% of them require grafts such as CryoVein and CryoArtery as an alternative to an autologous AV fistula.1 Up to 19% of patients with a synthetic hemodialysis graft have a graft infection.2 CryoVein and CryoArtery are ideal solutions to treat these infections and potentially save the hemodialysis site.3

The Ideal Grafts for:

  • Patients in whom an autologous AV fistula is not possible
  • Treating infected AV access grafts
  • Patients who are at risk of AV access infections
  • Patients with a limited number of AV access sites

Key Benefits:

  • 72% cumulative patency at 24 months4
  • Excellent resistance to infection4
  • Outstanding durability5
  • Same pulsatile flow dynamics & compliance as autografts6
icon-info Request More Information
Tissue Diameter Length Catalog Number
Femoral Vein 6mm - 15mm 10cm - 30+mm V060
Femoral Artery 4mm - 5+mm 10cm - 30+mm R020
Saphenous Vein 3mm - 6mm* 20cm - 80+cm* V010

*pressurized

References:
1. Scott E et al. Conduits for hemodialysis access. J Sem Vasc Surg 2007;158-163.
2. Akoh J. Prosthetic arteriovenous grafts for hemodialysis. J Vasc Access 2009;10:137-47.
3. Lin P et al. Management of infected hemodialysis access grafts using cryopreserved human vein allografts. Am J Surg 2002;184:31-6.
4. CryoLife data on file (ML0101).
5. Brown K et al. Arterial reconstruction with cryopreserved human allografts in the setting of infection: a single-center experience with midterm follow-up. J Vasc Surg 2009;49:660-6.
6. Bia D et al. Differential function coupling between human saphenous cryoallografts and arteries: importance of the arterial type and the biomechanical parameter evaluated. Artif Organs 2007;31(11):809-818.